Pulmonary Embolism Thrombolysis
Direct Answer
Systemic thrombolysis is indicated for high-risk pulmonary embolism (PE) with shock or persistent hypotension (systolic BP <90 mmHg for ≥15 minutes), and the recommended alteplase dose is 100 mg infused over 2 hours via peripheral IV. 1
Indications for Systemic Thrombolysis
High-Risk (Massive) PE - Class I Indication
Thrombolysis should be administered to all patients with high-risk PE unless absolute contraindications exist. 1
High-risk PE is defined by:
- Systolic blood pressure <90 mmHg, OR
- Pressure drop of ≥40 mmHg for >15 minutes (not due to arrhythmia, hypovolemia, or sepsis), OR
- Requirement for vasopressor support 1
The survival benefit is substantial in this population, with meta-analyses showing mortality odds ratio of 0.47 favoring thrombolysis despite bleeding risks. 2 In one small randomized study of massive PE with cardiogenic shock, all 4 patients receiving heparin alone died, while all 4 receiving thrombolysis survived—the study was stopped early for ethical reasons. 1
Intermediate-Risk (Submassive) PE - Selective Use Only
Routine primary thrombolysis is NOT recommended in hemodynamically stable patients with intermediate-risk PE. 1
However, rescue thrombolysis IS indicated (Class I) if hemodynamic deterioration occurs despite anticoagulation. 1
Intermediate-risk PE is defined by:
- Normal blood pressure (systolic ≥90 mmHg), AND
- Evidence of RV dysfunction (echocardiographic RV hypokinesis, RV dilation, or elevated biomarkers like troponin or BNP) 1
The PEITHO trial demonstrated that thrombolysis in stable intermediate-risk PE reduced hemodynamic decompensation but increased major bleeding (including 2% intracranial hemorrhage) without reducing 30-day mortality. 1 This risk-benefit profile does not support routine use in stable patients. 1
Low-Risk PE
Thrombolysis is contraindicated in low-risk PE. 1 These patients have <5% mortality with anticoagulation alone. 1
Absolute Contraindications
The following are absolute contraindications even in high-risk PE:
- History of hemorrhagic stroke or stroke of unknown origin (at any time) 1, 2
- Ischemic stroke within preceding 6 months 1, 2
- Central nervous system neoplasm or structural damage 1, 2
- Major trauma, surgery, or head injury within preceding 3 weeks 1, 2
- Active internal bleeding 1, 2
- Known bleeding diathesis 1, 2
Critical caveat: In life-threatening high-risk PE with shock, most traditional "absolute" contraindications become relative because the mortality risk (>15%) exceeds bleeding risk. 2 The only true absolute contraindications that persist are active hemorrhage and recent hemorrhagic stroke. 2
Relative Contraindications
These should be weighed against mortality risk, particularly in high-risk PE:
- Transient ischemic attack within 6 months 1, 2
- Current oral anticoagulation 1, 2
- Pregnancy or within 1 week postpartum 1, 2
- Non-compressible vascular punctures 1, 2
- Traumatic cardiopulmonary resuscitation 1, 2
- Refractory hypertension (systolic >180 mmHg) 1, 2
- Advanced liver disease 1, 2
- Infective endocarditis 1, 2
- Active peptic ulcer 1, 2
In high-risk PE with shock, relative contraindications should NOT prevent thrombolysis because early mortality exceeds 15% and outweighs bleeding risk. 2
Recommended Alteplase Dosing Regimen
Standard FDA-Approved Regimen (Preferred)
Alteplase (rtPA) 100 mg as continuous IV infusion over 2 hours via peripheral vein 1
- Withhold anticoagulation during the 2-hour infusion 1
- Resume unfractionated heparin (without bolus) after completion 1
- This regimen provides faster hemodynamic improvement than 12-24 hour regimens 1
Alternative Accelerated Regimen (Not FDA-Approved)
Alteplase 0.6 mg/kg over 15 minutes (maximum 50 mg) 1, 3
- Used in extreme hemodynamic instability or cardiac arrest 1
- One study in massive PE with shock showed 76% survival with this regimen 3
- Lower bleeding rates observed (11% major bleeding) compared to 2-hour regimen (21-24%) in some studies, though not statistically significant 1
Alternative Thrombolytic Agents
If alteplase unavailable:
The 2-hour streptokinase regimen achieves similar hemodynamic efficacy to alteplase by 2 hours, despite slower initial improvement at 1 hour. 4
Practical Algorithm for Decision-Making
Step 1: Risk Stratify the PE
- High-risk: Shock or persistent hypotension → Proceed to Step 2
- Intermediate-risk: Stable BP + RV dysfunction → Anticoagulation alone; thrombolyze only if deteriorates
- Low-risk: Stable BP + no RV dysfunction → Anticoagulation alone; no thrombolysis
Step 2: Assess for Absolute Contraindications
- Recent hemorrhagic stroke or active bleeding?
Step 3: Administer Thrombolysis
- Alteplase 100 mg IV over 2 hours 1
- If extreme instability/cardiac arrest: Consider 0.6 mg/kg bolus over 15 minutes 1, 3
- Imaging confirmation is preferred but not mandatory if patient too unstable 1
Step 4: If Thrombolysis Contraindicated or Fails
- Surgical pulmonary embolectomy (preferred alternative) 1, 2
- Catheter-directed thrombectomy (if surgery unavailable or too high-risk) 1, 5
Critical Pitfalls to Avoid
Do not delay thrombolysis for angiographic confirmation in unstable patients. Bedside echocardiography showing RV dysfunction plus high clinical probability is sufficient. 1 Angiography increases bleeding complications. 1
Do not withhold thrombolysis in high-risk PE due to relative contraindications alone. The mortality benefit outweighs bleeding risk when shock is present. 2
Do not routinely thrombolyze intermediate-risk PE. The PEITHO trial showed no mortality benefit and increased bleeding. 1 Reserve for hemodynamic deterioration only. 1
Early administration matters. Studies suggest that earlier thrombolysis in high-risk PE reduces mortality and bleeding complications compared to delayed administration. 6
Major bleeding occurs in approximately 13% of patients, with intracranial hemorrhage in 1.8%. 2 This risk is acceptable in high-risk PE but not in stable intermediate-risk disease.